Lummy(SZ:300006)2025-04-23 10:20Financial Performance - The company's revenue for Q1 2025 was ¥198,396,229.11, representing a 9.54% increase compared to ¥181,120,476.19 in the same period last year[3] - The net loss attributable to shareholders for Q1 2025 was ¥13,775,322.52, compared to a loss of ¥4,575,299.38 in Q1 2024[3] - Total operating revenue for the current period reached ¥198,396,229.11, an increase of 9.5% compared to ¥181,120,476.19 in the previous period[20] - Net loss for the current period was ¥13,959,616.84, compared to a profit of ¥31,378.00 in the previous period[21] - Basic and diluted earnings per share were both reported at -0.0130, compared to -0.0043 in the previous period, reflecting a decline in profitability[21] Cash Flow - The net cash flow from operating activities was -¥42,007,338.52, a decrease of 153.02% from ¥79,222,721.89 in the previous year[11] - The company's cash flow from operating activities showed a decline, indicating potential challenges in cash generation[23] - Cash received from operating activities totaled 298,863,067.81, while cash paid for operating activities was 340,870,406.33, leading to a negative cash flow[24] - Total cash inflow from financing activities was 52,509,161.10, while cash outflow was 188,813,252.93, resulting in a net cash flow of -136,304,091.83[25] - The net increase in cash and cash equivalents was -222,800,277.40, down from an increase of 118,514,005.21 in the previous period[25] Assets and Liabilities - Total assets decreased by 7.51% to ¥2,641,469,294.02 from ¥2,855,799,671.54 at the end of the previous year[3] - The total current assets decreased from 1,770,099,007.74 RMB to 1,532,370,297.08 RMB[17] - The total non-current assets increased from 220,174,591.57 RMB to 241,121,244.03 RMB in long-term equity investments[17] - Total liabilities decreased to ¥768,310,894.67 from ¥972,467,655.35 in the previous period, showing improved financial leverage[19] - The company’s total liabilities decreased by 43.31% in short-term borrowings, from ¥242,914,255.80 to ¥137,700,000.00[8] Research and Development - Research and development expenses increased by 33.71% to ¥13,768,411.89 from ¥10,297,554.56 in the same period last year[9] - Research and development expenses increased to ¥13,768,411.89, up from ¥10,297,554.56 in the previous period, reflecting a focus on innovation[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 304,323[13] - The largest shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., holds 23.43% of shares, totaling 247,426,064 shares[13] - Shareholder Qiu Yu holds 10.52% of shares, totaling 111,090,200 shares, which are currently frozen[13] Other Income and Expenses - The company reported a significant decrease in other income, down 77.81% to ¥4,408,944.53 from ¥19,870,791.47 in Q1 2024[9] - Total operating costs increased to ¥207,297,310.76, up 8.5% from ¥190,903,145.49 in the previous period[20] - The company paid 59,535,625.16 in cash to employees during the period[24] Investments - The company participated in an investment of 40 million RMB in Guangdong Dongna Collaborative Industry Investment Partnership[15] - The company has received drug registration certificates for two specifications of injectable Nicorandil, 2mg and 12mg[16] - The company plans to continue the disposal of 674,800 shares held by Qiu Yu through centralized bidding due to overdue debts[15] - The company has a total of 188,688,328.50 RMB in inventory at the end of the reporting period[17] Asset Disposal - The company experienced a 212.91% increase in asset disposal gains, rising to ¥25,052.59 from ¥8,006.35 in Q1 2024[9]